Valeo Pharma Inc. (VPHIF)
| Market Cap | 99.00 |
| Revenue (ttm) | 38.64M |
| Net Income (ttm) | -23.25M |
| Shares Out | 98.68M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 457,599 |
| Open | 0.0000 |
| Previous Close | 0.0001 |
| Day's Range | 0.0000 - 0.0000 |
| 52-Week Range | 0.0000 - 0.0003 |
| Beta | 0.79 |
| RSI | 36.87 |
| Earnings Date | n/a |
About Valeo Pharma
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization through all stages. The company offers access to product specialists and medical information for healthcare professionals and patients. Valeo Pharma se... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2023, Valeo Pharma's revenue was 53.91 million, an increase of 94.31% compared to the previous year's 27.75 million. Losses were -27.81 million, 8.01% more than in 2022.
Financial numbers in CAD Financial StatementsNews
Valeo Pharma Earnings Call Transcript: Q3 2024
Q3 2024 revenues declined 11% year-over-year due to the loss of Xiidra, but core business grew 9% excluding Xiidra. Cost-saving measures improved adjusted EBITDA loss by 40%, and the company targets EBITDA positive in Q1 2025. REDESCA and respiratory units showed strong growth.
Valeo Pharma Earnings Call Transcript: Q2 2024
Q2 2024 saw record revenues and continued growth in core brands, despite a higher net loss driven by product mix and Xiidra's exit. Major restructuring aims to cut costs and support EBITDA breakeven by year-end, with strong momentum in respiratory and hospital segments.
Valeo Pharma Transcript: AGM 2024
Valeo Pharma Earnings Call Transcript: Q1 2024
Valeo Pharma Earnings Call Transcript: Q4 2023
Valeo Pharma Earnings Call Transcript: Q3 2023
Valeo Pharma Earnings Call Transcript: Q2 2023
Valeo Pharma Transcript: AGM 2023
Valeo Pharma Transcript: Bloom Burton & Co Healthcare Investor Conference
Valeo Pharma Earnings Call Transcript: Q1 2023
Valeo Pharma Earnings Call Transcript: Q4 2022
Valeo Pharma Earnings Call Transcript: Q3 2022
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for AR...
Valeo Pharma Transcript: Status update
Valeo Pharma Earnings Call Transcript: Q2 2022
Valeo Pharma Transcript: AGM 2022
Valeo Pharma Earnings Call Transcript: Q1 2022
Valeo Pharma Earnings Call Transcript: Q4 2021
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC") Public reimbursement now includes Ontario...
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
Hesperco now available in approximately 300 stores under the Loblaws banners Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, Jan. 5, 20...
Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon 85% private payer health plan coverage across Canada MON...
/C O R R E C T I O N from Source -- Valeo Pharma inc./
In the news release, Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada, issued 13-Oct-2021 by Valeo Pharma inc. over CNW, we are advised by the company...
Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada
2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The...